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“Critical analysis of the use of statistical tests in Brazilian 
publications related to digestive tract surgery”1 analyzes the 
strength of evidence and use of statistical tests in two peri-
ods, 1987 and 2007, in national gastroenterological surgical 
publications. It concluded that: an increase in animal stud-
ies (from 3.33% to 19.7%) was observed; the distribution of 
studies according to the strength of the evidence remained 
intact (randomized assays [less than 3%] and non-random-
ized, prospective or historical cohorts, and case control 
studies); and the use of statistical tests increased from 40% 
to 70%, despite a significant impact in the adequate use hav-
ing not been observed.
Despite implicit limitations in the evaluation of the two 
periods, this analysis indicates how scientific information 
generation in surgical gastroenterology has been among us. 
This is done with an explicit and reproducible method, in a 
clear, objective, and understandable way, providing elements 
for a few reflections, which are exposed below.
Whenever we approach the subject “level or strength of 
the evidence published”, it should be done with at least two 
points of view: regarding the consequences of the clini-
cal decision and the consequences of the evaluation of the 
publisher.
The strength of the evidence translates the level of uncer-
tainty, inherent to the inferences of publications regarding 
the effects on patients by described or executed interven-
tions2. Statistical tests should only be useful when the level 
of uncertainty is small, confirming or not the applicability, 
with expectations of practical results similar to those of the 
study. The consequences of publication-based decision mak-
ing is directly proportional to the level of their uncertainties 
and, therefore, the lower the strength the greater the risk of 
an unpredictable result regarding the effects on patients.
Currently, assessing the quality of the publisher and/or 
author is limited to a series of superficial indicators3, such as 
the number of quotes obtained along a determined period 
of time or publication in international journals, regardless 
of the strength of the evidence of said publications or the 
strength of evidence of the publications that quote them. 
Proposals of analysis like that of the work of Orso IRB et al.1, 
reach some stakeholders and have a few consequences:
1. On readers: they should be able to identify the level of 
uncertainty of the published evidence when considering 
them in their decisions;
2. On peer review: should make explicit the strength of 
evidence related to publications approved;
3. On quality reviewers: they should review their indica-
tors, giving the appropriate weight to publishers and/or 
authors depending on the strength of the evidence pub-
lished;
4. On authors: they should make an effort to produce and 
spread information with an elevated level of evidence 
strength, protecting patients of dubious decisions re-
garding the outcome;
5. On research backers: they should support and stimulate 
investigators capable of developing practicable projects 
to answer each category of clinical question;
6. On universities: they should strengthen, through post-
graduation programs, initiatives that contemplate the 
production of relevant, new, strong, and applicable prod-
ucts, stimulating publication in national journals;
7. On publishers: they should occupy their place as opin-
ion makers, contributing appropriately with the health 
system, since they are responsible for making public 
consistent, and inconsistent, scientific information.
This study by Orso IRB et al.1 reproduces several inter-
national experiences4-7, with variations on the distribution 
of the proportions of strength of the evidence published, 
which are directly responsible for the need of appropriate 
statistical tests. The deficiencies of the statistical tests used 
are not a major problem, since they are the effect, and not 
the cause, of the weakness of the evidence generated8.
This example of quality assessment should be followed 
and valued, since it strengthens the notion of a Medicine 
that considers patient experience and values, but also the 
scientific evidence that permeates this physician-patient 
relationship.
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